Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Schlaak

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 10, 2019
Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differencesMoritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2017
Prognostic factors and treatment outcomes in 444 patients with mucosal melanomaMarkus V Heppt, Alexander Roesch, Benjamin Weide, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2021
Robustness of convolutional neural networks in recognition of pigmented skin lesionsRoman C Maron, Sarah Haggenmüller, Christof von Kalle, et al.
Frontiers of Medicine|July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trialElias A T Koch, Anne Petzold, Anja Wessely, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 InhibitionMax Schlaak, Carolina Cimminiello, Jacopo Pigozzo, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 10, 2019
Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differencesMoritz Felcht, Claus-Detlev Klemke, Jan Peter Nicolay, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2021
Clinical determinants of long-term survival in metastatic uveal melanomaElias A T Koch, Anne Petzold, Anja Wessely, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2017
Prognostic factors and treatment outcomes in 444 patients with mucosal melanomaMarkus V Heppt, Alexander Roesch, Benjamin Weide, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2021
Robustness of convolutional neural networks in recognition of pigmented skin lesionsRoman C Maron, Sarah Haggenmüller, Christof von Kalle, et al.
Frontiers of Medicine|July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trialElias A T Koch, Anne Petzold, Anja Wessely, et al.
Pageof 10